asia pacific cancer biomarkers market
DESCRIPTION
Asia Pacific is a potential market for Biomarkers. Growing at a robust compounded annual growth rate of 16% during the period 2013-2020, the global market is projected to touch US $13 billion. Biomarkers are chemical, physical or biological parameters which can be used to indicate disease states. Oncology biomarkers offers high speed, non invasive cancer diagnosis and believe to enhance cancer detection and screening. Major driving factors for the market are streamlined drug delivery process, noninvasive technology, increased rates of survival. Increase boost in government and private funding for oncology also fuels the market growth. Market is constrained by high cost of diagnosis, issues related to reimbursement and some of the regulatory policies which hinder the market growth. Government agencies such as Food and Drug Administration (FDA) and the National Cancer Institute (NCI) have taken an active interest in the field. Asia-Pacific biomarkers market is segmented based on type of applications, By service. Asia-Pacific Cancer Biomarker market is segmented based on Cancer biomarker discovery market , and cancer biomarker diagnostic market and based on geography divided into India, China, Japan . Some of the major players in this market are Dr. Reddy's Laboratories Limited (India),GVK Biosciences Private Limited (India), Human Metabolome Technologies Inc. (Japan), Ocimum Biosolutions Ltd. (India), Ranbaxy Laboratories Limited (India), Takeda Pharmaceutical Company Limited (Japan) What makes our report Unique? 1) A wide and in depth analysis of various applications, and services provided in Global Biomarker market as well as cancer biomarker market. 2) We provide longest possible market segmentation based on the type of cancers, applications of biomarkers( Risk assessment, disease diagnosis, drug formulation, forensic application) Services( Sample preparation, Assay development, biomarkers validation and testing) 3) We provide you a complete competitive landscape which includes major players in the market, mergers and acquisitions, Collaborations and new product launches.TRANSCRIPT
ASIA PACIFICCANCER BIOMARKERSMARKET
Market Shares, Forecasts& Trends
2014 - 2019
mordorintelligence.com
REPORT DESCRIPTION
Asia Pacific is a potential market for Biomarkers. Growing at a robust compounded annual growth rate of 16%
during the period 2013-2020, the global market is projected to touch US $13 billion.
Biomarkers are chemical, physical or biological parameters which can be used to indicate disease states.
Oncology biomarkers offers high speed, non invasive cancer diagnosis and believe to enhance cancer detection
and screening.
Major driving factors for the market are streamlined drug delivery process, noninvasive technology, increased
rates of survival. Increase boost in government and private funding for oncology also fuels the market growth.
Market is constrained by high cost of diagnosis, issues related to reimbursement and some of the regulatory
policies which hinder the market growth. Government agencies such as Food and Drug Administration (FDA) and
the National Cancer Institute (NCI) have taken an active interest in the field.
Asia-Pacific biomarkers market is segmented based on type of applications, By service. Asia-Pacific Cancer
Biomarker market is segmented based on Cancer biomarker discovery market , and cancer biomarker diagnostic
market and based on geography divided into India, China, Japan .
Some of the major players in this market are Dr. Reddy's Laboratories Limited (India),GVK Biosciences Private
Limited (India), Human Metabolome Technologies Inc. (Japan), Ocimum Biosolutions Ltd. (India), Ranbaxy
Laboratories Limited (India), Takeda Pharmaceutical Company Limited (Japan)
What makes our report Unique?
1. A wide and in depth analysis of various applications, and services provided in Global Biomarker market
as well as cancer biomarker market.
2. We provide longest possible market segmentation based on the type of cancers, applications of
biomarkers( Risk assessment, disease diagnosis, drug formulation, forensic application) Services(
Sample preparation, Assay development, biomarkers validation and testing)
3. We provide you a complete competitive landscape which includes major players in the market, mergers
and acquisitions, Collaborations and new product launches.
SAMPLE FIGURES
Oncology Biomarker Discovery Market
micro RNA
2013 2014 2015 2016 2017 2018 2019 2020
Asia Pacific Market Size (USD billion)
2009 2010 2011 2012 2013 2014 2015
Global Cancer Biomarker Market Growth
TABLE OF CONTENTS
1. INTRODUCTION
1.1 Objective
1.2 Key findings and observations
1.3 Research methodology
1.4 Market stakeholders
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
3.1 Definition of the market
3.2 Market growth estimation
3.3 Market size estimation
3.4 Classification of Cancer biomakers
3.5 Technologies used in Identifying cancer biomakers
4. Biomarkers Indication Market
4.1 Oncology Biomarkers Market
4.2 Cardiology biomarkers market
4.3 Neurology biomarkers market
4.4 Others Indication Biomarkers Market
4.5 Disease types
4.6 Renal failure
4.7 Arthritis
4.8 Tuberculosis
4.9 Diabetes
5. Asia_Pacific Biomarkers market segmentation
5.1 Market segmentation, By type of applications
5.1.1 Risk Assesment
5.1.2 Devlopment of molecular diagnostics
5.1.3 Disese diagnosis
5.1.4 Drug discovery and development
5.1.5 Drug formulation
5.1.6 Forensic application
5.1.7 Others(DNA fingerprinting and others)
5.2 Market segmentation, By Services
5.2.1 Sample preparation
5.2.2 Assay developement
5.2.3 Biomakers validation and testing
5.3 market Segmentation, By geography
5.3.1 India
5.3.2 China
5.3.3 Japan
5.3.4 Australia
5.3.5 ROA
6. Cancer Biomarkers Market
6.1 Introduction
6.2 Oncology Biomarkers Market
6.3 Oncology biomarkers Discovery market
6.3.1 Genomics
6.3.2 Proteomics
6.3.3 Metabolomics
6.3.4 Transcriptomics
6.3.5 Other Omics
6.3.6 Imaging
6.4 Cancer Biomarkers Diagnostic Market
6.4.1 Immunohistochemical (IHC) tests
6.4.2 Molecular (DNA and genomic) diagnostic assays
6.4.3 Genetic and genomic markers
6.4.4 Proteomics
6.4.5 Flow cytometry
6.4.6 Stem cell markers
6.4.7 Monoclonal antibodies
6.4.8 Pharmacogenomics
6.4.9 DNA microarrays
6.4.10 IVD multivariate index assays (IVDMIA)
7 Market Dynamics
7.1 Market Drivers
7.1.1 Non invasive technologies
7.1.2 Increased survival rates
7.1.3 Enhanced accuracy and Speed of diagnosis
7.1.4 Streamlined drug delivery process
7.1.5 Helps in FDA approval of drugs
7.1.6 Boost in government and Private funds for biomarkers discovery
7.2 Market Restraints
7.2.1 High cost of diagnosis
7.2.2 Reimbursement issues
7.2.3 Need for immediate processing
8. Competitive Landscape
8.1 Introduction
8.2 New product launches
8.3 Market strategies
8.4 Agreements, Partnerships & expansion
8.5 Mergers and Acquisitions
9. Company Profiles
Dr. Reddy's Laboratories Limited (India
GVK Biosciences Private Limited (India),
Human Metabolome Technologies Inc. (Japan)
Ocimum Biosolutions Ltd. (India
Ranbaxy Laboratories Limited (India),
Takeda Pharmaceutical Company Limited (Japan)
ABOUT US
Mordor Intelligence is a global market research and consulting firm. Our singular focus is to provide research
insights for business success.
Our research team has expertise in diverse fields like Agriculture, Healthcare, ICT, Chemicals, Manufacturing,
Logistics, Electronics and Automotive. However diverse the expertise maybe, everyone in our team shares one
common trait - we love data and we love providing solutions to clients using that data even more. Seeing your
business flourish based on our solutions and strategy is what we love the most.
DISCLAIMER
Mordor Intelligence Reports and their contents, including all the analysis and research containing valuable market
information, are provided to a select group of customers in response to orders. Our customers acknowledge when
ordering that Mordor Intelligence strategic analysis services are for our customers’ internal use and not for
general publication or disclosure to third parties.
Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation. Mordor
Intelligence takes no responsibility for any incorrect information supplied to us by manufacturers or users.
No part of this strategic analysis service may be given, lent, resold or disclosed to non-customers without written
permission. Reproduction and/or transmission in any form and by any means including photocopying,
mechanical, electronic, recording or otherwise, without the permission of the publisher is prohibited.
For information regarding permissions and sales, please contact: [email protected]
7 | Mordor Intelligence !
!
Mordor Intelligence LLP No. 30, Padma Nilaya, Chola Nagar Bangalore, Karnataka, India 560032
+1 781 881 1110 | [email protected]
Copyright © 2014 Mordor Intelligence LLP All Rights Reserved. This document contains highly confidential information and is the sole property of Mordor Intelligence LLP. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Mordor Intelligence LLP.